© 1992-2025 Cisco Systems, Inc. All rights reserved. | Privacy Statement | Cookie Policy | Terms of Use

Cisco Learning Labs Scheduling Tool — Production System. Product & Services; Support; How to Buy; Training & Events; Partners; You need to sign in or sign up before continuing. Proceed to …

May 14, 2015 · Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) is usually diagnosed in asymptomatic patients with early-stage disease. The standard management …

Mar 1, 2021 · The Chinese Society of Clinical Oncology (CSCO) guidelines for FL is applicable for patients with grade FL1−3a. Patients with grade FL3b and histologically-transformed …

Feb 19, 2025 · Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) is the most common leukemia in the Western hemisphere. The majority of patients who require treatment …

CSCO 2022 . SEQUOIA: Results of a Phase 3 Randomized Study of Zanubrutinib versus Bendamustine + Rituximab (BR) in Patients with Treatment -Naïve (TN) Chronic Lymphocytic …

Objective: Bruton tyrosine kinase (BTK) inhibitors are approved for chronic lymphocytic leukemia (CLL), but intolerability and treatment resistance can limit their use. There is a clinical need for …

Conclusions: In ALPINE, patients with R/R CLL/SLL treated with zanubrutinib demonstrated improvement over those treated with ibrutinib on the QLQ-30 GHS/QOL scale at cycle 7 (6 …

This video will help you work within the lab environment, once you’ve successfully connected to the lab portal. Briefly describe the article. The summary is used in search results to help users …

Mar 11, 2025 · Therapeutic advances in chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) have led to a paradigm shift from chemoimmunotherapy to targeted therapies …